The Antiandrogenic Effect of Finasteride Against a Mutant Androgen Receptor
May 2011
in “
Cancer Biology & Therapy
”
Studysummary This study found that finasteride decreased DHT-stimulated AR activity and cell growth in prostate cancer cells with mutant AR, but not in those with wild type AR.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the antiandrogenic effect of finasteride against a mutant androgen receptor (AR) in prostate cancer cells. The results showed that finasteride was able to inhibit the growth of LNCaP cells, but not VCaP cells. The study also compared the AR antagonistic effect of finasteride to that of bicalutamide, a non-steroidal antiandrogen, and found them to be comparable. The study suggests that finasteride could affect AR signaling beyond limiting the production of DHT, and additional studies are needed to investigate the susceptibility of various AR mutants to finasteride. The study concludes that finasteride could be beneficial in improving the outcome of androgen deprivation therapy for prostate cancer.
